News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 672 results
November 2018
-
Media ReleaseFDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication- Promacta receives FDA approval for first-line treatment of severe aplastic anemia (SAA) and Breakthrough Therapy designation for low platelet counts in people exposed to radiation- Approval based…
-
Media ReleaseFDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication
-
Media ReleaseNovartis to fund five innovative ideas to support patients and the sickle cell community- 2018 STEP Program™ designed to support unique proposals from nonprofit organizations that serve people living with sickle cell disease- Novartis will select proposals that demonstrate innovation in…
-
Media ReleaseNovartis to fund five innovative ideas to support patients and the sickle cell community
-
Media ReleaseNew Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patientsEntresto® (sacubitril/valsartan) outperformed commonly used heart failure medicine enalapril in landmark study; delivered significantly greater and more rapid reductions in an established biomarker…
-
Media ReleaseNew Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients
-
Media ReleaseNovartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology- Additional analysis from pivotal Phase III SOLAR-1 clinical trial studying investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) and fulvestrant in patients with PIK3CA-mutated HR+/HER2…
-
Media ReleaseNovartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology
October 2018
-
Media ReleaseNovartis wins esteemed Prix Galien Foundation Best Biotechnology Product Award for CAR-T cell therapy, Kymriah®-- Kymriah was the first CAR-T cell therapy to ever be approved by a regulatory authority-- Since 1970, more than 40 Novartis innovative therapies have been recognized by the Prix Galien Foundation…
-
Media ReleaseNovartis wins esteemed Prix Galien Foundation Best Biotechnology Product Award for CAR-T cell therapy, Kymriah®
-
Media ReleaseTwo-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD- Year two results consistent with previously announced key secondary endpoint data on retinal fluid (IRF and/or SRF) showing superior reductions versus aflibercept- Superior reductions in central…
Pagination
- ‹ Previous page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- …
- 56
- › Next page